TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Sitagliptin on Postprandial Lipoprotein Metabolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* type 2 diabetes~* dietary therapy~Exclusion Criteria:~* lipid-lowering therapy~* anti-hyperglycemic drug therapy

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- sitagliptin (Type: EXPERIMENTAL): None
- glimepirid (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: VA Gastrointestinal (GI) Quality of Life Survey

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18+ years of age~* Able to understand English~Exclusion Criteria:~* Diagnosed dementia, severe TBI or other conditions which limit the ability to provide acute information in the judgment of the investigators.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: None): SCI or disabled
- 2 (Type: None): Able-bodied

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Bioabsorbable Staple Line Reinforcement in Colorectal,Coloanal and Ileoanal Anastomoses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who will undergo restorative proctectomy or proctocolectomy (\<10 cm from anal verge) with a low circular stapled colorectal, coloanal or ileoanal anastomosis with or without reservoir, including treatment for rectal cancer, ulcerative colitis, familial adenomatous polyposis~  , diverticulitis, perforation of the bowel/trauma.~* Subjects undergoing Hartmann's reversal with restorative proctectomy (\<10 cm from the anal verge).~* Subjects may or may not have a diverting loop ileostomy as a component of their initial surgery.~* Subjects who meet the requirements of number 1 and 2, and are being treated for rectal cancer may or may not have preoperative chemoradiation therapy in the treatment of their rectal cancer.~Exclusion Criteria:~* Subjects being treated for rectal cancer with a diagnosis of inflammatory bowel disease.~* Subjects who have significant intraoperative hypotension or cardiac events.~* Subjects with collagen vascular disease, coagulopathy, significant renal or hepatic dysfunction (creatinine \>1.6 or liver enzymes \> 50% upper limit of normal values).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Device (Type: ACTIVE_COMPARATOR): GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement configured for circular staplers
- Procedure/Surgery (Type: OTHER): Procedure/Surgery: colorectal, coloanal, and ileoanal anastomotic staple line without reinforcement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Noninvasive Estimation of Work of Breathing

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult medical/surgical ICU patients (Age≥18) on mechanical ventilation for respiratory failure, spontaneously breathing and receiving eligible for pressure support ventilation (PSV).~Exclusion Criteria:~* Prisoners and patients with closed-head injury (e.g., trauma), hemodynamic instability, multiple organ system failure or late term pregnancy will not be studied.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Observational Group (Type: OTHER): Patients receiving mechanical ventilation and subject to the intervention: changes in ventilator settings.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of an Immunotoxin on Activated Human Macrophages in Those With Allergic Rhinitis or Mild Intermittent Asthma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Physician diagnosis of atopy (allergic rhinitis or mild intermittent asthma)~* Age 18-55 years~* Nonsmoker (\> 5 years)~* Forced expiratory volume in 1 second (FEV1) \> 70% of the predicted value~* A positive skin prick test for grass mix or D. pteronyssinus at or within 12 months prior to the screening visit~* Informed consent~* Females with negative pregnancy test~Exclusion Criteria:~* Infections of the respiratory tract within the last month~* Past or present disease, which as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, hematological disease, neurological disease, endocrine disease or pulmonary disease (including but not confined to chronic bronchitis, emphysema, tuberculosis, bronchiectasis or cystic fibrosis).~* Pathological findings in blood tests (differential blood count, blood clotting, electrolytes, liver enzymes, retention parameters)~* Subject is undergoing allergen desensitization therapy~* Permanent medication~* Systemic or inhaled corticosteroid use within the last month~* Anti-inflammatory medication within the last month~* Pregnancy~* Neurological or psychiatric disease or history of drug or alcohol abuse which would interfere with the subject's proper completion of the protocol assignment~* There is a risk of non-compliance with study procedures~* Participation in a clinical trial 30 days prior to enrolment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Handheld Ultrasound Evaluation of the Inferior Vena Cava to Guide Heart Failure Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a diagnosis of congestive heart failure~* NYHA class II-IV (ambulatory only)~* left ventricular systolic dysfunction with ejection fraction (EF) \< 50%~* history of hospitalization for heart failure within the last year (ambulatory only)~* age \>18 years old~* admission to heart failure service (inpatient arm only)~Exclusion Criteria:~* Patients with dyspnea not mainly due to heart failure~* valvular disease requiring surgery~* acute coronary syndromes within the previous 10 days~* revascularization within the previous month~* body mass index higher than 35~* serum creatinine level higher than 2.49 mg/dL~* a life expectancy of less than 3 years from noncardiovascular diseases (ambulatory arm only)~* a life expectancy of less than 1 year from noncardiovascular disease (inpatient arm only)~* non-cardiovascular causes of acute renal failure present on admission that preclude the use of diuretics (inpatient arm only)~* unable to give informed consent~* no follow-up possible~* participating in another study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Handheld ultrasound - inpatient (Type: EXPERIMENTAL): Handheld Ultrasound IVC Diameter Guided Diuretic Therapy Handheld ultrasound of the IVC diameter is used to guide diuretic therapy
- Sham ultrasound - inpatient (Type: SHAM_COMPARATOR): Conventional Symptom Guided Diuretic Therapy conventional clinical care as would occur outside of the study. These patients receive a sham ultrasound to facilitate blinding
- Handheld ultrasound - ambulatory (Type: EXPERIMENTAL): Handheld Ultrasound IVC Diameter Guided Diuretic Therapy Handheld ultrasound of the IVC diameter is used to guide diuretic therapy in the ambulatory setting during normal clinic visits.
- Sham ultrasound - ambulatory (Type: SHAM_COMPARATOR): Conventional Symptom Guided Diuretic Therapy conventional clinical care as would occur outside of the study. These patients receive a sham ultrasound to facilitate blinding in the ambulatory setting during normal clinic visits.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Propranolol Versus Prednisolone for Treatment of Symptomatic Hemangiomas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* infants with symptomatic hemangiomas~Exclusion Criteria:~* asthma~* diabetes~* hypertension~* hypotension~* hypoglycemia~* liver failure~* previous treatment for hemangiomas

- Gender: ALL
- Minimum Age: 2 Weeks
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- propranolol for treatment of hemangiomas (Type: EXPERIMENTAL): Assessing efficacy and tolerability of propranolol in management of symptomatic hemangiomas
- Prednisolone (Type: ACTIVE_COMPARATOR): Assessing efficacy and tolerability of prednisolone in management of symptomatic hemangiomas and comparing to propranolol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed cHL, sALCL, or other CD30-expressing PTCL~* Previously treated with brentuximab vedotin containing regimen, with evidence of objective response, and subsequent disease progression or relapse after discontinuing treatment~* Documentation of disease relapse or progression ≥6 months after the last dose of brentuximab vedotin~* Fluorodeoxyglucose positron emission tomography- (FDG-PET) avid and bidimensional measurable disease of at least 1.5 cm in longest axis as documented by radiographic technique~* Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2~* Must not be pregnant and, if of childbearing or fathering potential, must agree to use 2 effective contraception methods during study and for 6 months following last dose of study drug~Exclusion Criteria:~* Previously discontinued brentuximab vedotin due to any Grade 3 or higher toxicity~* Existing Grade 2 or higher peripheral neuropathy~* Previously refractory to treatment with brentuximab vedotin~* History of a cerebral vascular event, unstable angina, or myocardial infarction within 6 months prior to first dose~* History of another malignancy within 3 years before first dose of study drug or any evidence of residual disease from previously diagnosed malignancy~* Acute or chronic graft-versus-host-disease (GvHD) or receiving immunosuppressive therapy as treatment for or prophylaxis agent against GvHD~* Active cerebral/meningeal disease~* History of progressive multifocal leukoencephalopathy (PML)~* Active uncontrolled Grade 3 (per NCI CTCAE v5.0) or higher viral, bacterial, or fungal infection within 2 weeks prior to first dose of study drug~* Chemotherapy, radiotherapy, biologics, and/or other antitumor treatment with immunotherapy that is not completed 4 weeks prior to first dose of study drug, unless underlying disease has progressed on treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brentuximab vedotin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Analgesic Effect of Laser Therapy in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Tonsillectomy or adenotonsillectomy due to apneic chronic snoring and/or obstructive sleep apnea and/or recurrent tonsillitis~Exclusion Criteria:~1. American Society of Anesthesiologists (ASA) Score \> 2~2. Neuropsychiatric co-morbidity~3. Pro-hemorrhage coagulation disorders

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Laser (Type: EXPERIMENTAL): Laser light will be applied to the surgery site after tonsils excision.
- Standard care (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African American and Hispanic Origin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female of 50-85 years of age~2. Subjects with recent COVID-19 diagnosis (within 72 hours), that are symptomatic (fever, cough, SOB, weakness, or other flu-like symptoms).~3. Agrees to comply with study procedures (diary, oximeter readings, telephone follow up).~4. Has given voluntary, written, informed consent to participate in the study.~5. Identifies as African American or Hispanic Origin~6. Patients must have at least 1 risk factor (history of hypertension (BP\> 140/99) CHF, angina, prior MI, coronary angiography with one significantly occluded vessel, diabetes mellitus, obesity, or smoking, (for at least 5 years).~Exclusion Criteria:~1. Females who are pregnant, breastfeeding or planning to become pregnant during the course of the study.~2. Patients unresponsive or unable to take anything by mouth (NPO).~3. Individuals who are cognitively impaired and/or who are unable to give informed consent.~4. Blood pressure below 110 mmHg systolic and 60 mmHg diastolic on entry into study.~5. History of syncope or other symptoms of orthostatic hypotension.~6. History of methemoglobinemia.~7. Severe case of G6PD deficiency

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Nitric Oxide (Type: ACTIVE_COMPARATOR): Nitric Oxide (NO) lozenges taken twice daily by mouth for 30 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo of Nitric Oxide (NO) lozenges taken twice daily by mouth for 30 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Low Dose Fat for the Prevention of Liver Disease in Babies With Gastrointestinal Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* congenital or acquired gastrointestinal disorder~* age less than 5 days of life~Exclusion Criteria:~* congenital intrauterine infection know to be associated with liver involvement~* known structural liver abnormalities~* known genetic disorders (trisomy 21, 13, and 18)~* inborn errors of metabolism~* infants meeting the criteria for terminal illness (ph:6.8\>2 hours)

- Gender: ALL
- Minimum Age: 1 Minute
- Maximum Age: 5 Days
- Healthy Volunteers: f

Study Arms:
- low dose intravenous fat emulsion (Type: EXPERIMENTAL): Subjects in this arm will receive approximately 1 g/kg/d IV of intravenous soybean oil (Intralipid).
- standard dose intravenous fat emulsion (Type: ACTIVE_COMPARATOR): Subjects in this arm will receive approximately 3 g/kg/d IV of intravenous soybean oil (Intralipid).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Death Following Congenital Heart Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients in the congenital surgery database~* Post-operative surgical mortality~* Deaths within 30 days of surgery~* Deaths prior to ever leaving the hospital

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing to participate in the study~* Age 18 years old or older~* Eastern Cooperative Oncology Group Performance Status less than or equal 2~Exclusion Criteria:~* Age less than 18 years old~* Not willing to participate in the study~* Vulnerable subjects or Eastern Cooperative Oncology Group Performance Status 3 or 4

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Denosumab (Type: ACTIVE_COMPARATOR): Denosumab 60 MG/ML Prefilled Syringe~Denosumab Dose: 60 milligrams, subcutaneous injection, every 6 months (twice a year)
- Zoledronic Acid (Type: ACTIVE_COMPARATOR): Zoledronic Acid 5Mg/Bag 100Ml Inj~Zoledronic acid will be 5 milligrams, Intravenous injection, once a year

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Ultrasound in Obstetric Neuraxial Analgesia and Anesthesia Data Base

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women in labor or scheduled for induction requesting labor epidural analgesia~* Pregnant women scheduled for cesarean delivery~* Pregnant women in labor who are going to have a non-emergent cesarean delivery under spinal anesthesia~Exclusion Criteria:~* Emergency delivery~* Emergency cesarean section~* Advanced labor~* Contraindications to neuraxial analgesia/anesthesia~* Unable to understand consent~* Under the age of 18

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Ultrasound of the spine (Type: None): Pregnant women receiving labor epidural analgesia or spinal anesthesia for cesarean delivery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Low-dose Epinephrine Infusion Tests in Adolescent and Pediatric Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients ages 3-18 years~2. Patients undergoing device closure of an atrial septal defect in the cardiac catheterization lab~3. normal electrocardiogram without prolonged absolute or corrected QT interval(less than 440 msec)~Exclusion Criteria:~1. Patients with a history of any other structural or acquired heart disease besides the atrial septal defect.~2. Patient with a family history of sudden cardiac death, or personal history of syncope.~3. Patient on alpha or beta-blocking medications.~4. Pregnancy.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Epinephrine (Type: EXPERIMENTAL): Healthy pediatric subjects will receive epinephrine. Epinephrine infusion will begin at 0.025 ug/kg/minute, for ten minutes.The epinephrine infusion will then be increased to 0.05 ug/kg/minute for five minutes. The epinephrine infusion will then be increased to a maximal dose of 0.1 ug/kg/minute for five minutes. The epinephrine infusion is then discontinued.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues